Digital therapeutics (DTx) have emerged as an interesting addition to conventional pharmacological solutions, offering innovative ways to improve patient compliance and enhance treatment outcomes. Traditional pharma companies are increasingly recognizing the potential of DTx, but often lack the digital skills and agility found in tech start-ups. This has set the stage for collaborations between promising start-ups and established pharma companies. However, the partnership dynamics differ from traditional biotech-pharma collaborations due to the unique nature of digital health technologies, different regulatory requirements and the contrasting organizational cultures between the two industries.
Comments